Skip to content

High Flow Nasal Oxygen Therapy an Implementation Study in Pediatric Wards

High Flow Nasal Oxygen Therapy an Implementation Study in Pediatric Wards

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06715423
Acronym
HFNO
Enrollment
960
Registered
2024-12-04
Start date
2025-01-31
Completion date
2025-12-31
Last updated
2025-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Moderate Respiratory Distress, Severe Respiratory Distress

Keywords

oxygen, high flow, pneumonia, pediatrics

Brief summary

The purpose of this study is to prospectively evaluate the process of implementing HFNO in several MSF projects, varying according to geographical and programmatic contexts, population, health structures, human resources, and management. It will generate evidence on the operational feasibility (in terms of human resources, equipment, logistics and costs) of integrating HFNO into PICU standard of care, as well as on the users' and caregivers' perspectives on HFNO and on the children clinical outcomes observed where HFNO is implemented. This relevant information will guide MSF in the decision making of scaling up HFNO therapy in its projects.

Detailed description

Mixed method study: quantitative component for the data of the children and qualitative data for the perception for health staffs and parents

Interventions

None listed

Sponsors

MOH Afghanistan
CollaboratorUNKNOWN
MOH Bangladesh
CollaboratorUNKNOWN
MOH Sierra Leone
CollaboratorUNKNOWN
MOH Yemen
CollaboratorUNKNOWN
MSF Médecins Sans Frontières Belgium
CollaboratorUNKNOWN
MSF Médecins Sans Frontières France
CollaboratorUNKNOWN
Fisher and Paykel Healthcare
CollaboratorINDUSTRY
Epicentre
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
1 Months to 5 Years
Healthy volunteers
No

Inclusion criteria

* prescription of HFNO by clinician * parent consenting to the use of the data

Design outcomes

Primary

MeasureTime frame
Recovery with SPO2 above 92%From enrollment to day 3 to 10

Other

MeasureTime frameDescription
Acceptability, feasibility and perception from the caretaker point of view2 weeks after hospitalisationinterview of the caretaker
Acceptability, feasibility and perception from the health staff point of viewFrom Month 2 until Month 12Interview of the health staffs (doctors, nurses, biomed, managers, logisticians)

Countries

Afghanistan

Contacts

Primary ContactElisabeth Poulet, MD, Msc
elisabeth.poulet@epicentre.msf.org0033140215465

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026